A Swiss Cancer Research grant to Prof. Francesco Bertoni

Prof. Francesco Bertoni has received a three-years financial support to study the mechanism of resistance to the combination of copanlisib and venetoclax in marginal zone lymphomas. The project, with PD Anastasios Stathis and Prof. Andrea Alimonti as co-applicants, follows the design of the phase I study SAKK 66/18 (NCT03886649). The trial has indeed just opened the recruitment and is based on Prof. Bertoni’s group preclinical work. The project supported by the Swiss Cancer Research (KFS-4727-02-2019) aims to dissect the mechanisms of resistance to the combination and it will employ genetic and pharmacological screening, development of in vitro and in vivo resistance models and the study of adaptive mechanisms.